Cost-Effectiveness, the QALY, and the evLYG - ICER As researchers that understand the appropriate and ethical use of cost-effectiveness, ICER has drafted a blueprint for policymakers seeking solutions on how to ensure proper use of the QALY in legislation:
Explore Our Research - ICER ICER formally launched ICER Analytics™, a new cloud-based platform that will revolutionize the ability of payers, life science companies, patient groups, and others to develop formularies, negotiate drug prices
Value Assessment Framework - ICER The ICER value framework describes the conceptual framework and set of associated methods that guide the development of ICER evidence reports
Assessments | Explore Our Research - ICER Find our most recent treatment assessments, or search from our archive of past assessments to find studies relating to treatments that matter to you
Methods Process | Our Approach - ICER ICER is driven by a mission to conduct evidence-based reviews of health care interventions, such as drug, devices and diagnostics, that help patients, doctors, and everyone else in the health care system know what works ICER has a developed a Value Assessment Framework, which is the foundation of our work
What is ICER | Institute for Clinical Economic Review Founded in 2006 and non-profit incorporated in 2013, ICER has become the nation’s non-partisan, independent, go-to-resource for objective evidence about the value of health care in the U S ICER’s appraisals of more than 100 drugs for more than 50 medical conditions, in addition to multiple devices and diagnostics, have demonstrated that
Launch Price and Access Report: Drug Approvals from 2023-2024 - ICER ICER will conduct a new analysis it plans to release on an annual basis titled the “Launch Price and Access Report” which will examine launch pricing for FDA-approved treatments This report will review the affordability and access of the treatments and their value to the overall health system
Institute for Clinical and Economic Review Publishes Evidence . . . - ICER In collaboration with patients, clinical experts, and other key stakeholders, ICER analyzes the available evidence on the benefits and risks of these interventions to measure their value and suggest fair prices ICER also regularly reports on the barriers to care for patients and recommends solutions to ensure fair access to prescription drugs